Lv51
950 积分 2021-04-16 加入
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
10分钟前
已完结
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
13分钟前
已完结
Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes
3天前
已完结
Global trends and regional variations in PCa burden: A focus on China's rapid growth
3天前
已完结
Effect Of Crossover-Surgery At The Subsequent Relapse On The Survival Of Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Prespecified And Post-Hoc Analyses Of The SOC-1 Randomized Phase 3 Trial
17天前
已关闭
Effect Of Crossover-Surgery At The Subsequent Relapse On The Survival Of Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Prespecified And Post-Hoc Analyses Of The SOC-1 Randomized Phase 3 Trial
17天前
已关闭
早防早治宫颈癌,这个检查能帮您
18天前
已关闭
医联体内宫颈疾病双向转诊模式的研究
18天前
已关闭
Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data
18天前
已完结
Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial
18天前
已完结
皖公网安备34019202002308
